THE CHALLENGE
UK biotech financing is recovering. Venture capital into UK biotechs reached £516 million in Q1 2026, up 17% on the previous quarter, and the UK remains Europe’s largest biotech venture market with a 58% share of all European financing. Scotland’s life sciences sector is targeting a jump from £10.5 billion to £25 billion in turnover by 2035. North East England now hosts a National MedTech and In-Vitro Diagnostics Co-operative found nowhere else in the UK. None of that growth reaches your business automatically. Every one of those investors, NHS innovation leads and pharma partners will look you up online before they reply to an email, and for an early-stage life sciences venture with a limited budget, the question isn’t whether you need a website. It’s whether the one you have is doing its job.
01 – A cost is something you minimise. An investment is something you measure.
Rent is a cost. You want it as low as possible without compromising the lab space you need. A website is different: it’s a choice, and a well-built one is meant to pay for itself many times over, not just sit there as a line on the balance sheet.
The trouble is that most life sciences websites get built like a cost rather than an investment. A founder deep in a funding round asks a freelancer or a generalist agency for “something that looks professional,” a few weeks pass, and the result is a site that says the right words innovative, pioneering, world-class without doing any of the specific jobs a life sciences audience actually needs done.
The reframe
A biotech or medtech website earns its keep the same way a piece of lab equipment does: by producing a measurable return. If it isn’t shortening your fundraising conversations, helping NHS or pharma partners self-qualify, or making it easier to recruit the scientists you need, it’s an expense wearing an investment’s clothing.
02 – What investors, NHS partners and pharma leads actually check first
Due diligence into a private company almost always starts with an online search, long before a term sheet or an NDA is on the table. Standard due diligence guidance for evaluating any private company points investors straight to the company website: what it says about the product, the management team’s experience, and how long the business has actually been operating. For a life sciences venture, that first pass either builds confidence or creates doubt before a human conversation has even happened.
This matters more, not less, in a recovering market. The BioIndustry Association’s most recent figures show 24 UK biotech VC deals in Q1 2026, up 60% year-on-year, with capital spread across a broader base of companies rather than concentrated in a handful of megadeals. That’s good news for early-stage ventures outside the golden triangle of London, Oxford and Cambridge but it also means more companies competing for the same investor attention, and a thinner, less polished website is what gets a company filtered out of a shortlist before anyone picks up the phone.
“Investors evaluating a private company almost always start with the same three questions: what does it do, who’s running it, and how long has it been doing it. Your website answers all three before you’re in the room, or it raises doubts before you get there.”
The North East & Scotland life sciences opportunity, in numbers
Why the audience reading your website is bigger, and better funded, than it was two years ago
£516m
UK biotech venture capital raised in Q1 2026, up 17% on the previous quarter
£25bn
Scotland’s life sciences turnover target for 2035, up from £10.5bn today
46,000
Jobs already supported by Scotland’s life sciences sector
£2bn+
UK Government funding committed under the Life Sciences Sector Plan
Sources: BioIndustry Association, Q1 2026 biotech financing update; Scottish Government, Life Sciences Strategy for Scotland (Nov 2025); UK Government, Life Sciences Sector Plan (Jul 2025).
03 – The five jobs your website actually has to do
Strip away the design opinions and every life sciences website exists to do a small number of specific jobs. If yours isn’t doing these, no amount of visual polish will turn it into an asset.
- Establish credibility fast – the product, the team, the evidence, in the first thirty seconds
- Give investors and partners 24/7 access to the information they need before a call, not just after one
- Showcase your actual science, clearly enough that a non-specialist and a specialist both understand what you do
- Attract the talent you need in a region where 52% of employers already report skills gaps
- Start a conversation – a clear, specific call to action, not a generic “get in touch”
Notice what isn’t on that list: how many animations the homepage has, or whether the logo is 10% bigger than a competitor’s. Design quality matters, but it’s in service of these jobs, not a substitute for them.
04 – Two ecosystems, two different stories to tell
A generic “we’re a life sciences company” website misses what makes North East England and Scottish ventures genuinely credible to the audiences that matter: proximity to specific, well-known infrastructure and a growing weight of regional investment behind them.
🏴
Scotland: a sector with a published, funded growth plan
Scotland’s refreshed Life Sciences Strategy, published November 2025, sets out a route from today’s £10.5 billion turnover to £25 billion by 2035, backed by £1 million in initial Scottish Government investment and a new industry-led Life Sciences Scotland Cluster. Pharmaceutical manufacturing already generates gross value added of around £200,700 per worker over three times the Scottish average and the sector already earns over 20% of the UK’s commercial clinical trial revenue. A Scottish life sciences website that doesn’t reference this national strategy, or the University of Edinburgh, Glasgow and Dundee research base behind it, is leaving credibility on the table.
Source: Scottish Government, Life Sciences Strategy for Scotland (November 2025); Life Sciences Scotland.
🌊
North East England: a cluster built around named, checkable assets
Newcastle Helix and NETPark aren’t abstract cluster branding they’re specific, well-documented science parks with named tenants like ReproCELL Europe and Magnitude Biosciences, and named national facilities: the National Innovation Centre for Ageing, the National Innovation Centre for Data, the International Centre for Life, and the National Healthcare Photonics Centre at CPI. Newcastle is the only UK city with both a MedTech and In-Vitro Diagnostics Co-operative and an MRC/EPSRC Molecular Pathology Node. A regional life sciences website that names these assets directly, rather than gesturing vaguely at “world-class facilities,” reads as credible to someone doing due diligence from London, Boston or Basel.
Source: Invest North East England; UK Science Park Association (UKSPA); North East Technology Park (NETPark).
05 – Strategy first. Design second. Always in that order.
Every website strategy, life sciences or otherwise, answers the same four questions before a single page is designed:
- Where are we now? A clear, honest read of the current site and the current stage of the business
- Where do we want to go? Specific goals: an investor meeting, an NHS pilot, a talent pipeline, a partnership enquiry
- How will we know it’s working? A KPI tied to each goal, tracked from a baseline, not a vague sense of “more traffic”
- How do we get there? Messaging, information architecture, content and calls to action built around the audience’s decision-making process, not the founder’s personal taste in design
Skip this and you get a website that looks fine and does nothing measurable. A short conversation about layout and colour palette isn’t a strategy, however confident it feels in the room. The most common and most expensive mistake is treating those two things as the same conversation.
06 – What “credible” actually looks like for a regional life sciences site
Sector-specific knowledge changes what a website strategy needs to include. A life sciences audience reads differently to a general consumer audience, and a North East or Scottish life sciences audience has its own specific expectations again: regional research credentials, named facilities, regulatory awareness, and evidence that you understand the NHS and public sector procurement landscape you’re likely selling into.
“A website that doesn’t share your purpose, your evidence and your regional credibility won’t start the conversations you need it to. That’s not a design problem. It’s a strategy problem.”
Getting this right is exactly the sector-specific work that generic web design agencies, however skilled, routinely miss. A biotech or medtech venture in Newcastle, Durham, Edinburgh or Glasgow deserves a website built by people who understand both the science and the regional ecosystem it operates inside not a template built for life sciences companies in general and adjusted with a new logo.
Is your website an expense, or an investment?
Read Marketing works with biotech, medtech and medical device ventures across the North East and Scotland to build websites and digital strategies that earn their keep, not just look the part.
Leave a Reply